Conclusion
Many studies have implicated tyrosine phosphatases in the down-regulation of growth factor signaling pathways. It is becoming evident that some of them, including SHP-1, SHP-2 and PTPη, have a role in SSTR signaling. However, there are many issues which remain to be clarified. These include the identification of SST-mediated pathways in which these PTPs participate, as well as their physiological substrates and binding partners and the precise molecular mechanisms, which permit their interaction with sst receptors and/or associated molecules. In addition, the respective role of these PTP for each receptor subtype pathway awaits further study. Genetic approaches including gene targeting, RNA interference (RNAi) and new technologies including proteomic analysis and cell imaging for the detection and analysis of signalling complexes, will provide powerful tools to elucidate these important questions.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Patel YC. Molecular pharmacology of somatostatin receptor subtypes. J Endocrinol Invest 1997; 20:348–67.
Hierowski MT, Liebow C, du Sapin K, Schally AV. Stimulation by somatostatin of dephosphorylation of membrane proteins in pancreatic cancer MIA PaCa-2 cell line. FEBS Lett 1985; 179:252–6.
Liebow C, Reilly C, Serrano M, Schally AV. Somatostatin analogues inhibit growth of pancreatic cancer by stimulating tyrosine phosphatase. Proc Natl Acad Sci USA 1989; 86:2003–7.
Pan MG, Florio T, Stork PJ. G protein activation of a hormone-stimulated phosphatase in human tumor cells. Science 1992; 256:1215–7.
Rivard N, Lebel D, Laine J, Morisset J. Regulation of pancreatic tyrosine kinase and phosphatase activities by cholecystokinin and somatostatin. Am J Physiol 1994; 266:G1130–8.
Dent P, Wang Y, Gu YZ, et al. S49 cells endogenously express subtype 2 somatostatin receptors which couple to increase protein tyrosine phosphatase activity in membranes and down-regulate Raf-1 activity in situ. Cell Signal 1997; 9:539–49.
Todisco A, Seva C, Takeuchi Y, Dickinson CJ, Yamada T. Somatostatin inhibits AP-1 function via multiple protein phosphatases. Am J Physiol 1995; 269:G160–6.
Florio T, Scorizello A, Fattore M, et al. Somatostatin inhibits PC C13 thyroid cell proliferation through the modulation of phosphotyrosine activity. Impairment of the somatostatinergic effects by stable expression of E1 A viral oncogene. J Biol Chem 1996; 271:6129–36.
Colas B, Cambillau C, Buscail L, et al. Stimulation of a membrane tyrosine phosphatase activity by somatostatin analogues in rat pancreatic acinar cells. Eur J Biochem 1992; 207:1017–24.
Zeggari M, Esteve JP, Rauly I, et al. Co-purification of a protein tyrosine phosphatase with activated somatostatin receptors from rat pancreatic acinar membranes. Biochemical Journal 1994; 303:441–8.
Florio T, Thellung S, Corsaro A, et al. Characterization of the intracellular mechanisms mediating somatostatin and lanreotide inhibition of DNA synthesis and growth hormone release from dispersed human GH-secreting pituitary adenoma cells in vitro. Clin Endocrinol (Oxf) 2003; 59:115–28.
Florio T, Rim C, Hershberger RE, Loda M, Stork PJ. The somatostatin receptor SSTR1 is coupled to phosphotyrosine phosphatase activity in CHO-K1 cells. Molecular Endocrinology 1994; 8:1289–97.
Buscail L, Esteve JP, Saint-Laurent N, et al. Inhibition of cell proliferation by the somatostatin analogue RC-160 is mediated by somatostatin receptor subtypes SSTR2 and SSTR5 through different mechanisms. Proceedings of the National Academy of Sciences of the United States of America 1995; 92:1580–4.
Reardon DB, Wood SL, Brautigan DL, Bell GI, Dent P, Sturgill TW. Activation of a protein tyrosine phosphatase and inactivation of Raf-1 by somatostatin. Biochemical Journal 1996; 314:401–4.
Sharma K, Patel YC, Srikant CB. C-terminal region of human somatostatin receptor 5 is required for induction of Rb and G1 cell cycle arrest. Mol Endocrinol 1999; 13:82–90.
Neel BG, Tonks NK. Protein tyrosine phosphatases in signal transduction. Curr Opin Cell Biol 1997; 9:193–204.
Hof P, Pluskey S, Dhe-Paganon S, Eck MJ, Shoelson SE. Crystal structure of the tyrosine phosphatase SHP-2. Cell 1998; 92:441–50.
Shultz LD, Schweitzer PA, Rajan TV, et al. Mutations at the murine motheaten locus are within the hematopoietic cell protein-tyrosine phosphatase (Hcph) gene. Cell 1993; 73:1445–54.
Douziech N, Calvo E, Coulombe Z, et al. Inhibitory and stimulatory effects of somatostatin on two human pancreatic cancer cell lines: a primary role for tyrosine phosphatase SHP-1. Endocrinology 1999; 140:765–77.
Bousquet C, Delesque N, Lopez F, et al. sst2 somatostatin receptor mediates negative regulation of insulin receptor signaling through the tyrosine phosphatase Shp-1. J Biol Chem 1998; 273:7099–106.
Pages P, Benali N, Saint-Laurent N, et al. sst2 somatostatin receptor mediates cell cycle arrest and induction of p27(Kipl). Evidence for the role of Shp-1. J Biol Chem 1999; 274:15186–93.
Lahlou H, Saint-Laurent N, Esteve JP, et al. sst2 Somatostatin receptor inhibits cell proliferation through Ras-, Rap1-, and B-Raf-dependent ERK2 activation. J Biol Chem 2003; 278:39356–71.
Lopez F, Ferjoux G, Cordelier P, et al. Neuronal nitric oxide synthase is a SHP-1 substrate involved in sst2 somatostatin receptor growth inhibitory signaling. Faseb J 2001; 17:17.
Rauly I, Saint-Laurent N, Delesque N, et al. Induction of a negative autocrine loop by expression of sst2 somatostatin receptor in NIH 3T3 cells. Journal of Clinical Investigation 1996; 97:1874–83.
Buscail L, Saint-Laurent N, Chastre E, et al. Loss of sst2 somatostatin receptor gene expression in human pancreatic and colorectal cancer. Cancer Research 1996; 56:1823–7.
Rochaix P, Delesque N, Esteve JP, et al. Gene therapy for pancreatic carcinoma: local and distant antitumor effects after somatostatin receptor sst2 gene transfer [see comments]. Hum Gene Ther 1999; 10:995–1008.
Benali N, Cordelier P, Calise D, et al. Inhibition of growth and metastatic progression of pancreatic carcinoma in hamster after somatostatin receptor subtype 2 (sst2) gene expression and administration of cytotoxic somatostatin analog AN-238. Proc Natl Acad Sci USA 2000; 97:9180–5.
Thangaraju M, Sharma K, Leber B, Andrews DW, Shen SH, Srikant CB. Regulation of acidification and apoptosis by SHP-1 and Bcl-2. J Biol Chem 1999; 274:29549–57.
Srikant CB, Shen SH. Octapeptide somatostatin analog SMS 201-995 induces translocation of intracellular PTP1C to membranes in MCF-7 human breast adenocarcinoma cells. Endocrinology 1996; 137:3461–8.
Guillermet J, Saint-Laurent N, Rochaix P, et al. Somatostatin receptor subtype 2 sensitizes human pancreatic cancer cells to death ligand-induced apoptosis. Proc Natl Acad Sci USA 2003; 100:155–60.
Stein-Gerlach M, Wallasch C, Ullrich A. SHP-2, SH2-containing protein tyrosine phosphatase-2. Int J Biochem Cell Biol 1998; 30:559–66.
Florio T, Yao H, Carey KD, Dillon TJ, Stork PJ. Somatostatin activation of mitogenactivated protein kinase via somatostatin receptor l (SSTR1). Mol Endocrinol 1999; 13:24–37.
Florio T, Arena S, Thellung S, et al. The activation of the phosphotyrosine phosphatase eta (r-PTP eta) is responsible for the somatostatin inhibition of PC C13 thyroid cell proliferation. Mol Endocrinol 2001; 15:1838–52.
Reardon DB, Dent P, Wood SL, Kong T, Sturgill TW. Activation in vitro of somatostatin receptor subtypes 2, 3, or 4 stimulates protein tyrosine phosphatase activity in membranes from transfected Ras-transformed NIH 3T3 cells: coexpression with catalytically inactive SHP-2 blocks responsiveness. Mol Endocrinol 1997; 11:1062–9.
Ferjoux G, Lopez F, Esteve JP, et al. Critical role of Src and SHP-2 in sst2 somatostatin receptor-mediated activation of SHP-1 and inhibition of cell proliferation. Mol Biol Cell 2003.
Trapasso F, Iuliano R, Boccia A, et al. Rat protein tyrosine phosphatase eta suppresses the neoplastic phenotype of retrovirally transformed thyroid cells through the stabilization of p27(Kip1). Mol Cell Biol 2000; 20:9236–46.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2004 Springer Science + Business Media, Inc.
About this chapter
Cite this chapter
Lahlou, H. et al. (2004). Somatostatin Receptor Signaling via Protein Tyrosine Phosphatases. In: Srikant, C.B. (eds) Somatostatin. Endocrine Updates, vol 24. Springer, Boston, MA. https://doi.org/10.1007/1-4020-8033-6_10
Download citation
DOI: https://doi.org/10.1007/1-4020-8033-6_10
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4020-7799-9
Online ISBN: 978-1-4020-8033-3
eBook Packages: Springer Book Archive